The Trump administration is preparing 100% tariffs on certain imported medicines, targeting companies that have not committed to increasing U.S. manufacturing, The Financial Times’ Aime Williams reports. The move follows earlier threats to impose such levies on branded or patented drugs, while companies including Pfizer (PFE), AstraZeneca (AZN), and Novo Nordisk (NVO) have secured exemptions by pledging greater U.S. investment and price reductions. Other publicly traded companies in the space include Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- 3 Vanguard ETFs Are Beating the S&P 500 in 2026 – Should You Buy?
- Best ETFs to Invest In, According to AI Analyst, 4/1/2026
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
- 3 Best ETFs to Invest In, According to AI Analyst, 03/30/2026